+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H1 2019

  • ID: 4767159
  • Drug Pipelines
  • 787 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • 3-V Biosciences Inc
  • AstraZeneca Plc
  • DURECT Corp
  • Immuron Ltd
  • Naia Ltd
  • Saje Pharma LLC
  • MORE
Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H1 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H1 2019, provides an overview of the Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) pipeline landscape.

Non-alcoholic steatohepatitis (NASH) is liver inflammation caused by a buildup of fat in the liver. NASH can get worse and cause scarring of the liver, which leads to cirrhosis. Symptoms of NASH include fatigue, weight loss for no clear reason, general weakness and an ache in the upper right part of belly. Risk factors include obesity, type 2 diabetes, high cholesterol and high triglycerides and metabolic syndrome.

Report Highlights

This latest pipeline guide Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Non-Alcoholic Steatohepatitis (NASH) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 8, 40, 42, 1, 5, 143, 49 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 1 molecules, respectively.

Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • 3-V Biosciences Inc
  • AstraZeneca Plc
  • DURECT Corp
  • Immuron Ltd
  • Naia Ltd
  • Saje Pharma LLC
  • MORE
Introduction

Non-Alcoholic Steatohepatitis (NASH) - Overview

Non-Alcoholic Steatohepatitis (NASH) - Therapeutics Development

Non-Alcoholic Steatohepatitis (NASH) - Therapeutics Assessment

Non-Alcoholic Steatohepatitis (NASH) - Companies Involved in Therapeutics Development

Non-Alcoholic Steatohepatitis (NASH) - Drug Profiles

Non-Alcoholic Steatohepatitis (NASH) - Dormant Projects

Non-Alcoholic Steatohepatitis (NASH) - Discontinued Products

Non-Alcoholic Steatohepatitis (NASH) - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Non-Alcoholic Steatohepatitis (NASH), H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by 3-V Biosciences Inc, H1 2019

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by 89bio Ltd, H1 2019

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Abide Therapeutics Inc, H1 2019

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by AdAlta Ltd, H1 2019

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Akcea Therapeutics Inc, H1 2019

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Akero Therapeutics Inc, H1 2019

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Albireo Pharma Inc, H1 2019

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Aldeyra Therapeutics Inc, H1 2019

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Allergan Plc, H1 2019

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Allinky Biopharma SL, H1 2019

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Alteogen Inc, H1 2019

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Angion Biomedica Corp, H1 2019

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Araim Pharmaceuticals Inc, H1 2019

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Arcturus Therapeutics Ltd, H1 2019

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Ardelyx Inc, H1 2019

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Ascletis Inc, H1 2019

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Assembly Biosciences Inc, H1 2019

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by AstraZeneca Plc, H1 2019

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Betagenon AB, H1 2019

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by BioElectron Technology Corp, H1 2019

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Bird Rock Bio Inc, H1 2019

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by BLR Bio LLC, H1 2019

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Boehringer Ingelheim GmbH, H1 2019

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Bristol-Myers Squibb Co, H1 2019

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Cadila Healthcare Ltd, H1 2019

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Can-Fite BioPharma Ltd, H1 2019

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Carmot Therapeutics Inc, H1 2019

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Celgene Corp, H1 2019

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Cerenis Therapeutics Holding SA, H1 2019

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by ChemoCentryx Inc, H1 2019

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by CJ HealthCare Corp, H1 2019

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by CohBar Inc, H1 2019

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Coherus BioSciences Inc, H1 2019

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by ConSynance Therapeutics Inc, H1 2019

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by ContraVir Pharmaceuticals Inc, H1 2019

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Corcept Therapeutics Inc, H1 2019

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by CymaBay Therapeutics Inc, H1 2019

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Daiichi Sankyo Co Ltd, H1 2019

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Debiopharm International SA, H1 2019

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Dicerna Pharmaceuticals Inc, H1 2019

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Dimerix Bioscience Pty Ltd, H1 2019

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2019

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by DURECT Corp, H1 2019

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Eli Lilly and Co, H1 2019

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Enanta Pharmaceuticals Inc, H1 2019

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Enyo Pharma SA, H1 2019

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Esperion Therapeutics Inc, H1 2019

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Exicure Inc, H1 2019

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Forma Therapeutics Inc, H1 2019

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Galectin Therapeutics Inc, H1 2019

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Galecto Biotech AB, H1 2019

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Galmed Pharmaceuticals Ltd, H1 2019

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Gemphire Therapeutics Inc, H1 2019

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Genfit SA, H1 2019

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by GenKyoTex SA, H1 2019

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Gilead Sciences Inc, H1 2019

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by GRI Bio Inc, H1 2019

Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Guangdong Zhongsheng Pharmaceutical Co Ltd, H1 2019

List of Figures

Number of Products under Development for Non-Alcoholic Steatohepatitis (NASH), H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Number of Products by Top 10 Targets, H1 2019

Number of Products by Stage and Top 10 Targets, H1 2019

Number of Products by Top 10 Mechanism of Actions, H1 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019

Number of Products by Top 10 Routes of Administration, H1 2019

Number of Products by Stage and Top 10 Routes of Administration, H1 2019

Number of Products by Top 10 Molecule Types, H1 2019

Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • 3-V Biosciences Inc
  • 89bio Ltd
  • Abide Therapeutics Inc
  • AdAlta Ltd
  • Akcea Therapeutics Inc
  • Akero Therapeutics Inc
  • Albireo Pharma Inc
  • Aldeyra Therapeutics Inc
  • Allergan Plc
  • Allinky Biopharma SL
  • Alteogen Inc
  • Angion Biomedica Corp
  • Araim Pharmaceuticals Inc
  • Arcturus Therapeutics Ltd
  • Ardelyx Inc
  • Ascletis Inc
  • Assembly Biosciences Inc
  • AstraZeneca Plc
  • Betagenon AB
  • BioElectron Technology Corp
  • Bird Rock Bio Inc
  • BLR Bio LLC
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Co
  • Cadila Healthcare Ltd
  • Can-Fite BioPharma Ltd
  • Carmot Therapeutics Inc
  • Celgene Corp
  • Cerenis Therapeutics Holding SA
  • ChemoCentryx Inc
  • CJ HealthCare Corp
  • CohBar Inc
  • Coherus BioSciences Inc
  • ConSynance Therapeutics Inc
  • ContraVir Pharmaceuticals Inc
  • Corcept Therapeutics Inc
  • CymaBay Therapeutics Inc
  • Daiichi Sankyo Co Ltd
  • Debiopharm International SA
  • Dicerna Pharmaceuticals Inc
  • Dimerix Bioscience Pty Ltd
  • Dong-A Socio Holdings Co Ltd
  • DURECT Corp
  • Eli Lilly and Co
  • Enanta Pharmaceuticals Inc
  • Enyo Pharma SA
  • Esperion Therapeutics Inc
  • Exicure Inc
  • Forma Therapeutics Inc
  • Galectin Therapeutics Inc
  • Galecto Biotech AB
  • Galmed Pharmaceuticals Ltd
  • Gemphire Therapeutics Inc
  • Genfit SA
  • GenKyoTex SA
  • Gilead Sciences Inc
  • GRI Bio Inc
  • Guangdong Zhongsheng Pharmaceutical Co Ltd
  • Hana Pharm Co Ltd
  • Hanmi Pharmaceuticals Co Ltd
  • HemoShear Therapeutics, LLC
  • HotSpot Therapeutics Inc
  • IB Pharmaceuticals Inc
  • Immupharma Plc
  • Immuron Ltd
  • Indalo Therapeutics Inc
  • Integral Molecular Inc
  • Intercept Pharmaceuticals Inc
  • Inventiva
  • Inversago Pharma Inc
  • Ionis Pharmaceuticals Inc
  • Kowa Co Ltd
  • Kyorin Pharmaceutical Co Ltd
  • LG Chem Ltd
  • LifeMax Laboratories Inc
  • Lin Bioscience Inc
  • Lipocine Inc
  • Madrigal Pharmaceuticals Inc
  • MallInckrodt Plc
  • MedImmune LLC
  • Merck & Co Inc
  • Metabolys SAS
  • Metacrine Inc
  • Mina Therapeutics Ltd
  • Mitsubishi Tanabe Pharma Corp
  • Naia Ltd
  • Nash Pharmaceuticals Inc
  • NeuroVive Pharmaceutical AB
  • NGM Biopharmaceuticals Inc
  • Nippon Chemiphar Co Ltd
  • Novartis AG
  • Novo Nordisk AS
  • Nuevolution AB
  • NuSirt Biopharma Inc
  • Oramed Pharmaceuticals Inc
  • Pfizer Inc
  • Phanes Therapeutics Inc
  • Pharmaxis Ltd
  • Phenex Pharmaceuticals AG
  • Pliant Therapeutics Inc
  • Poxel SA
  • Promethera Biosciences SA
  • ProMetic Life Sciences Inc
  • Protalix BioTherapeutics Inc
  • Redx Pharma Plc
  • Regulus Therapeutics Inc
  • reMYND NV
  • Ritter Pharmaceuticals Inc
  • Saje Pharma LLC
  • Sancilio & Company Inc
  • Sanofi
  • ScandiCure AB
  • Second Genome Inc
  • Seres Therapeutics Inc
  • SFA Therapeutics LLC
  • Shenzhen HighTide Biopharmaceutical Ltd
  • Sihuan Pharmaceutical Holdings Group Ltd
  • Synlogic Inc
  • T3D Therapeutics Inc
  • TaiwanJ Pharmaceuticals Co Ltd
  • Terns Pharmaceuticals Inc
  • Tiziana Life Sciences Plc
  • TRACON Pharmaceuticals Inc
  • Vascular Biogenics Ltd
  • Verlyx Pharma Inc
  • Viking Therapeutics Inc
  • Visionary Pharmaceuticals Inc
  • Vivus Inc
  • WAVE Life Sciences Ltd
  • Yuhan Corp
  • Zafgen Inc
  • Zebra Discovery Ltd
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4767159
Adroll
adroll